Ofatumumab Impresses in MS; Competition for Ocrelizumab Soon? Ofatumumab Impresses in MS; Competition for Ocrelizumab Soon?
A new B cell-depleting therapy, given as a monthly subcutaneous injection, has shown impressive results in two phase 3 studies in relapse-remitting multiple sclerosis.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
More News: Allergy | Allergy & Immunology | Brain | Multiple Sclerosis | Neurology | Neurosurgery | Study